Background- We aimed to assess the magnitude of the problem of Cardiovascular risk factors in hospitalized patients and to establish Cardiovascular disease (CVD) risk factor profiles.Methods- We selected 476 confirmed CVD patients by a multi-stage stratified cluster random sampling technique in Tabriz Heart Center. After obtaining demographic information and performing physical examination, we measured biochemical parameters. Data were analyzed with SPSS 10.05, and p<0.05 was considered significant.Results- Obesity was the most common abnormality (93.5%), followed by diabetes mellitus (58.4%), low levels of high-density lipoprotein cholesterol (HDL-c) (45.4%), low physical activity (41.6%), high total cholesterol (TC) (40.1%), high triglycerides (TG) (37.2%), high low-density lipoprotein cholesterol (LDL-c) (30.7%), diastolic hypertension (28.4%), high systolic blood pressure (24.8%) and smoking (20%). Ninety-three percent, 43%, 16% and 5% of patients had one, two, three and four risk factors for CVD, respectively. The prevalence of lipid disorders in females was more than that in males, except for low HDL-c (p<0.05). Among the lipid profiles, only TG had a relationship with age (p<0.05). Obesity was accompanied by lipid profile abnormality, such that low serum levels of HDL-c and high levels of TG, TC and LDL-c were more common in obese patients (p<0.05).Conclusion- This study revealed a high prevalence of risk factors in the CVD patients; thus modification of lifestyles is urgently needed.

Ferroptosis is a new type of programmed cell death that plays an important role in various Cardiovascular diseases, such as myocardial infarction, reperfusion injury, and heart failure. Cardiomyocyte loss is the most important determinant of morbidity and mortality, so, it is crucial to fully understand the regulatory mechanisms of ferroptosis signaling. In fact, inhibition of cardiac ferroptosis is a promising therapeutic strategy for Cardiovascular diseases. However, the biological and pathological contexts in which ferroptosis might operate are poorly defined. Herein we discuss the role of ferroptosis in various Cardiovascular diseases, provide an update on current knowledge about the molecular mechanisms that govern ferroptosis, and discuss about the role of ferroptosis inhibitors in control of ferroptosis induced Cardiovascular disease in animal models.